This study is evaluating the impact of initiating continuous glucose monitoring (CGM) in adults with type 2 diabetes on the progression of kidney disease and changes in glycemic control. Difference-in-difference models will be specified to evaluate pre-post changes in eGFR, urinary albumin excretion, and HbA1c.